Roles
Professor
Associate Director for Faculty Development, SCCC
-
Biography
Joseph Rosenblatt, M.D., is a Professor of Clinical Medicine and an endowed chair in the Division of Hematology. He serves as Associate Director for Faculty Development at Sylvester Comprehensive Cancer Center and is a physician-scientist with extensive experience in translational research and mentoring young investigators. He has been the institutional principal investigator on the American Cancer Society (ACS) Institutional Research Grant since 2006 and leads the ACS Diversity in Cancer Research (DICR) Internship Program, providing mentored research opportunities for underrepresented minorities.
Dr. Rosenblatt has over 25 years of experience as a Division Chief in Hematology/Oncology, including at the University of Rochester (1995–2001) and the University of Miami (2001–2021). He maintained an active clinical practice focused on lymphoid malignancies while leading translational research programs in viral oncology, gene therapy, and immunotherapy.
He has received numerous awards, including the NHLBI Physician-Scientist Award, NIH Shannon Award, multiple NCI R01 grants, LLS awards, and Department of Defense awards. He has served on multiple NIH, NCI, VA, and DOD study sections and panels, including NCI Special Emphasis Panels for SPORE reviews, and has been involved in international collaborations, including the AACR meeting on translational cancer research in Jerusalem.
Dr. Rosenblatt has trained numerous fellows and laboratory investigators who have pursued successful academic and industrial research careers. He has served on the SCCC Scientific Steering Committee, the Cancer Education Leadership Council (CELC), and has been recognized with mentoring awards including the Barkin/Rogers Mentoring Award (2017) and the SCCC Mentoring Award (2021). -
Education & Training
Education
Post Graduate Training
-
Research Interests
The Rosenblatt laboratory has engaged in development of novel antibody-based bi-functional molecules with the ability to promote an enhanced anti-angiogenic response, or to enhance a local anti- tumor immune response. Many of these molecules represented totally unique approaches including development of antibody fusions directed against the HER2 tyrosine kinase expressed on a subset of breast, ovarian and other solid tumors, as well as more recent anti-EGFR directed fusion proteins in triple negative breast cancer . Many of these have had unique conceptual and biologic activities such as ability to deliver a costimulatory ligand by antibody (B7.1 fusion), chemotactic stimulus through coupling of a chemokine, or local delivery of an anti-angiogenic peptide, which markedly enhances the anti- tumor efficacy of endostatin and uniquely inhibits angiogenesis, vessel co-option, and vasculogenic mimicry by solid tumors , as well as lymphoid malignancies.
The Rosenblatt lab was a pioneer in the early development of novel gene therapy-based approaches designed to augment anti-tumor immune response. These contributions include the development of HSV based amplicon vectors in collaboration, the combined use of chemokine and costimulatory ligand delivery to augment response, and demonstration of the ability to enhance immunogenicity of hematologic malignancies such as CLL using HSV amplicons
The Rosenblatt laboratory was also among the first to demonstrate the potential immune suppressive effects of B regulatory cells in solid tumor models including EL-4 thymoma, MC-38 colon cancer, and EMT- 6 mammary carcinoma.
he role of B regulatory cells in solid tumor immune suppression is now increasingly appreciated and accepted.. These observations laid a conceptual foundation for similar observations in triple negative breast cancer, , and other solid tumors
the Rosenblatt also made numerous contributions to understanding of the molecular biology of. HTLV-I, HTLV-II and d pathogenesis of HTLV-1 in relation to adult. T cell leukemia-lymphoma as well as HTLV-1associated myelopathy -
Publications
Disclaimer: The information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, please use this link to inform our data team. Your feedback is greatly appreciated and helps us improve the quality of our content.